Catalyst Crew Technologies Corp. has transitioned from a dormant shell to a development-stage AI healthcare technology company focusing on Latin American markets, especially Venezuela. Its latest quarter reflects acquisition of core AI assets and organizational activity geared toward telehealth and analytics platforms, but it faces severe cash flow constraints and a substantial doubt about its ability to continue as a going concern. The business model centers on modular clinical decision-support platforms—CardioAI, PulmoAI, NeuroAI—and technology-enabled healthcare coordination services, though these remain uncommercialized. The company's growth prospects hinge on successful platform development, regulatory navigation in a challenging LATAM landscape, and capital raises to sustain operations.